Living Donor Liver Transplant for Unresectable Colorectal Cancer Liver Metastases The LIVERMORE Trial at Modena

What this Trial Is About

Researchers are evaluating the use of liver transplantation, including living donor liver transplant LDLT, partial graft, or whole graft from deceased donors, for patients with unresectable colorectal liver metastases CRLM. The study aims to assess overall and disease-free survival over five years, as well as secondary outcomes such as graft survival and donor safety and quality of life. Donor selection follows established institutional and national protocols. Participants who meet the criteria for unresectable CRLM will undergo screening and a waiting period during which they continue chemotherapy and have regular blood tests and imaging scans every 8 weeks. Donors are also screened according to institutional protocols. After informed consent, patients receive LDLT or liver graft transplantation. Post-transplant, patients and donors are followed up routinely, with tumor and graft status reassessed every 4 months for the first 3 years, then every 6 months thereafter. During the study, participants will have clinical assessments, blood tests including tumor markers, CT and PET scans, and ongoing monitoring of their health status. Donor outcomes and quality of life are also tracked. The total follow-up period extends to 5 years post-transplant, allowing researchers to evaluate long-term survival and safety outcomes comprehensively.

LDLT in Non Resectable Colo-rectal Cancer Liver Metastasis